Antipsychotic medications modulate dopamine activity across various neural circuits, leading to both therapeutic effects and distinct adverse reactions. Match each clinical presentation described below to the specific dopaminergic pathway whose dopamine D2 receptor blockade is most directly responsible for the observed outcome.
- Significant reduction in persecutory delusions and commanding auditory hallucinations following initiation of haloperidol.Mesolimbic pathway
- Development of severe bradykinesia, masked facies, and cogwheel rigidity two weeks after increasing the dose of risperidone.Nigrostriatal pathway
- Onset of secondary amenorrhea and milky breast discharge in a female patient treated with a high-potency first-generation antipsychotic.Tuberoinfundibular pathway
- Worsening of social withdrawal, avolition, and flattened affect following the initiation of high-dose fluphenazine.Mesocortical pathway
Cevap
The presentations map to the following pathways: Positive symptom relief is due to mesolimbic blockade. Parkinsonian symptoms are due to nigrostriatal blockade. Galactorrhea and amenorrhea are due to tuberoinfundibular blockade. Worsening negative symptoms are due to mesocortical blockade.
Each clinical outcome specifically maps to the physiological function of its underlying dopaminergic circuit when subjected to dopamine D2 receptor antagonism.
Adım Adım Çözüm
Anahtar Kavram
The clinical effects of antipsychotic medications correlate with their activity across four distinct dopaminergic pathways: mesolimbic (therapeutic efficacy for positive symptoms), mesocortical (exacerbation of negative symptoms), nigrostriatal (extrapyramidal symptoms), and tuberoinfundibular (hyperprolactinemia).